glucagon news

All news on glucagon (also known as glucagon (human), hyperglycemic factor, hyperglycemic-glycogenolytic factor, and GlucaGen): plants, production capacities, investments and involved companies.

7 June 2026

Boehringer Ingelheim: Survodutide Phase III shows up to 34% visceral and 63% liver fat reduction with limited lean mass loss

Phase III data show targeted visceral and liver fat reductions with minimal lean mass loss and sustained weight loss in obesity and MASLD populations.
21 May 2026

Lilly’s retatrutide achieves up to 30% weight loss in Phase 3 TRIUMPH-1

Phase 3 TRIUMPH-1: three doses met endpoints at 80 weeks with dose-related, substantial weight loss. 104-week extension in BMI≥35 showed further loss; cardiometabolic markers improved; GI AEs common.

Who will be producing glucagon in the future?

Find out with chemXplore Alpha

Learn more